ADARx Pharmaceuticals, Inc. (ADRX)
NASDAQ: ADRX · Real-Time Price · USD
19.35
+2.35 (13.82%)
At close: Sep 25, 2026, 4:00 PM EDT
18.99
-0.36 (-1.86%)
After-hours: Sep 25, 2026, 7:52 PM EDT
ADARx Pharmaceuticals Revenue
ADARx Pharmaceuticals had revenue of $746.00K in the quarter ending June 30, 2026, with 258.65% growth. This brings the company's revenue in the last twelve months to $6.13M. In the year 2025, ADARx Pharmaceuticals had annual revenue of $3.45M.
Revenue (ttm)
$6.13M
Revenue Growth
n/a
P/S Ratio
336.58
Revenue / Employee
$122,540
Employees
50
Market Cap
2.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.45M | - | - |
| Dec 31, 2024 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ADRX News
- 2 days ago - ADARx Pharmaceuticals opens at $22.10, IPO priced at $17 per share - TheFly
- 2 days ago - ADARx Pharmaceuticals indicated to open at $24, IPO priced at $17 - TheFly
- 2 days ago - ADARx Pharmaceuticals indicated to open at $28, IPO priced at $17 - TheFly
- 2 days ago - ADARx Pharmaceuticals raises $446.3 million in upsized US IPO - Reuters
- 3 days ago - ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - GlobeNewsWire
- 6 days ago - ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO - Reuters
- 23 days ago - ADARx Pharmaceuticals IPO Registration Document (S-1) - SEC
- 23 days ago - siRNA biotech ADARx Pharmaceuticals files for a $100 million IPO - Renaissance Capital